Zenas BioPharma, a clinical-stage global biopharmaceutical company dedicated to advancing immunology-based therapies, has announced a remarkable funding achievement of $225 million. This significant capital infusion underscores Zenas' commitment to becoming a leader in the development and commercialization of innovative treatments for patients suffering from autoimmune diseases. With a robust portfolio that showcases potentially differentiated therapeutics, the funding will play a crucial role in accelerating the clinical development of Zenas' pipeline, which targets areas of high unmet medical need. The funding will enable the company to further advance its pioneering research and development initiatives, refine its clinical trials, and expand its global operations. Zenas boasts an experienced leadership team and a network of strategic business partners, all of whom are committed to delivering transformative therapies that can substantially improve patients' lives. With this funding, Zenas is well-equipped to pursue its vision of addressing the persistent challenges faced by individuals living with autoimmune disorders, thereby dramatically enhancing treatment options within this critical healthcare sphere. As the biopharmaceutical landscape evolves, Zenas BioPharma stands poised to make significant strides, not only in the realm of immunology but also in addressing the broader implications of autoimmune diseases on patient quality of life. This funding marks a pivotal moment in Zenas' journey, allowing the company to explore new horizons and push the boundaries of what's possible in autoimmune therapeutics.
Zenas BioPharma Secures $225 Million in Funding to Advance Innovative Immunology Therapies
Recently funded 路 $225.0MHealthcare
Get the full Zenas BioPharma company profile
Access contacts, investors, buying signals & more
Other recently funded companies
View all
Laihua Online
Wuhan Laihua Information and Technology is an Internet leading source of information on educational opportunities for students to study in other countries especially in China. Either prospect is planning to come to China or is already in China for education (self-support or scholarship based) he will probably need one of the ranges of services we provide from Education, Translation, Notarization of legal documents to Internships & Jobs or Medical Tourism etc. It is a comprehensive directory of study abroad programs, including summer study abroad, service learning, intensive language programs and more. Wuhan Laihua Information and Technology first set out to fill the information gap between students with a desire to travel abroad to study and companies offering international programs.
$68.0M Series d
today
NEW ID
NEW ID is the latest subsidiary company of NEW, which has started up since August 2019 for a new digital contents/platform business domain. We are responsible for expanding the contents produced and acquired by NEW into various markets and creating our digital capabilities through partnering with a-lister digital content creators and providers in Korea.
